
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is attractive because its post-Veralto portfolio is now concentrated in higher-quality life sciences and diagnostics franchises with durable demand, recurring consumables revenue, and improving bioprocessing trends that support a credible path to 5-7% revenue growth and HSD-DD% EPS growth. The company also showed solid execution in 3Q26, with $6.55B of revenue, 3.0% core growth, 29.0% adjusted operating margin, and $2.11 of adjusted EPS, while free cash flow of $1.6B and 128% FCF-to-net-income conversion underscored earnings quality. Despite a conservative 2027 outlook and lingering headwinds in respiratory and China, the reported order strength, durable underlying demand, and continued capital deployment potential suggest further upside as end markets recover.
Bears say
Danaher is facing a difficult fundamental backdrop because key end markets are softening, including reduced spending from biopharmaceutical companies, lower government funding for research, and weaker purchases by hospital labs and clinics. The company’s bioprocess equipment recovery has been slow, with promised reshoring-related demand not yet showing up, while Life Sciences instrument demand continues to decline and diagnostics in China still weighs on results, even though sales there are now under $1B annually and pricing pressure has eased. Investor skepticism is also rising around acquisition execution, as several recent Life Sciences deals have failed to meet expectations, making a 15x P/E downside multiple plausible if growth frustrations persist.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Danaher (DHR) Forecast
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares